Replies to post #2164 on Pozen Inc. (POZN)

[surf1944]

7:31AM POZEN beats by $0.08, beats on revs (POZN) 6.31 : Reports Q2 (Jun) loss of $0.17 per share, $0.08 better than the Capital IQ Consensus Estimate of ($0.25); revenues fell 60.9% year/year to $1.8 mln vs the $1.73 mln consensus. The Company is currently preparing the New Drug Application (NDA) and is planning to seek approval for two dosage forms of PA, PA32540 and PA8140. As previously disclosed, during a pre-submission meeting for the Company's NDA for PA32540, the FDA suggested that the Company also seek approval for a lower dose formulation of the product containing 81 mg of aspirin. In light of recent discussions with the FDA regarding the NDA for PA32540, we are continuing to re-evaluate financial outlook for the year, and plan to update when complete assessment.

[surf1944]

7:30AM POZEN announces PA32540 provides superior antiplatlet effects over a standard of care regimen in a Phase 1 study (POZN) 6.64 : The data from the Co-Rx Study suggest that PA32540 given in conjunction with clopidogrel, dosed at least 10 hours apart, resulted in greater antiplatelet effects than synchronously administered EC aspirin, clopidogrel, and EC omeprazole, in healthy volunteers. These data were further presented at the European Society of Cardiologists 2012 Congress in Munich, Germany on August 26, 2012. PA32540, an investigational coordinated-delivery tablet of immediate-release omeprazole, a proton pump inhibitor, layered around pH-sensitive aspirin, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.